about
Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility.Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group.Identification of multiple risk variants for ankylosing spondylitis through high-density genotyping of immune-related lociAmerican College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network 2015 Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis.High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry.Evaluation of the patient acceptable symptom state as an outcome measure in patients with ankylosing spondylitis: data from a randomized controlled trial.Preliminary validation of the Knee Inflammation MRI Scoring System (KIMRISS) for grading bone marrow lesions in osteoarthritis of the knee: data from the Osteoarthritis InitiativeAssociation of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations.Spinal inflammation in the absence of sacroiliac joint inflammation on magnetic resonance imaging in patients with active nonradiographic axial spondyloarthritis14-3-3η is a novel mediator associated with the pathogenesis of rheumatoid arthritis and joint damageAssociation of variants at 1q32 and STAT3 with ankylosing spondylitis suggests genetic overlap with Crohn's diseaseMRI evidence of structural changes in the sacroiliac joints of patients with non-radiographic axial spondyloarthritis even in the absence of MRI inflammationCirculating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis.Rheumatoid arthritis association with the FCRL3 -169C polymorphism is restricted to PTPN22 1858T-homozygous individuals in a Canadian population.UGT2B17 copy number gain in a large ankylosing spondylitis multiplex familyAnkylosing spondylitis and current disease-controlling agents: do they work?Therapy for ankylosing spondylitis: new treatment modalities.Genetic dissection of acute anterior uveitis reveals similarities and differences in associations observed with ankylosing spondylitis.Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.New therapies for ankylosing spondylitis: etanercept, thalidomide, and pamidronate.Genome-wide association study of ankylosing spondylitis identifies non-MHC susceptibility loci.Major histocompatibility complex associations of ankylosing spondylitis are complex and involve further epistasis with ERAP1.ERAP2 is associated with ankylosing spondylitis in HLA-B27-positive and HLA-B27-negative patientsEarly medication use in new-onset rheumatoid arthritis may delay joint replacement: results of a large population-based study.High prevalence of symptomatic enthesopathy of the shoulder in ankylosing spondylitis: deltoid origin involvement constitutes a hallmark of disease.Anterior chest wall inflammation by whole-body magnetic resonance imaging in patients with spondyloarthritis: lack of association between clinical and imaging findings in a cross-sectional studyCan erosions on MRI of the sacroiliac joints be reliably detected in patients with ankylosing spondylitis? - A cross-sectional study.Imaging in ankylosing spondylitis.Serum levels of 14-3-3η protein supplement C-reactive protein and rheumatoid arthritis-associated antibodies to predict clinical and radiographic outcomes in a prospective cohort of patients with recent-onset inflammatory polyarthritisTargeting tumour necrosis factor alleviates signs and symptoms of inflammatory osteoarthritis of the knee.Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema.Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein.Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials.Assessing single joints in arthritis clinical trials.A prospective cohort study of 14-3-3η in ACPA and/or RF-positive patients with arthralgiaIs there a preferred method for scoring activity of the spine by magnetic resonance imaging in ankylosing spondylitis?Serum urate in chronic gout--will it be the first validated soluble biomarker in rheumatology?Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).The Canadian Rheumatology Association/ Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project.How does imaging help the clinician in the evaluation and management of spondyloarthritis?
P50
Q29417082-2266EBFD-1B4E-427B-A9DD-717B7EF05FA8Q30251968-B5B2E381-BDED-474D-98AA-535CE79500A9Q30417517-FCEF5925-2AB6-4221-9F22-778ED9ABC77DQ30829836-4F2B5CF3-D571-4F31-BA1C-3115852F95E0Q30959623-7208D763-68C3-4A74-BD38-FADE2CB8BC27Q31151311-447609D9-4B6A-4D73-9597-C5F3F07C06E8Q31156921-F76E3302-03ED-433A-864A-8D6DB9B9EDD6Q33218161-CB929723-25E3-49BB-A26C-347BE1196C9CQ33661893-ED09F57A-C3B0-4E76-A5BC-B12D598DAE01Q33766367-C07D6FE9-C5E6-4E06-B09B-14978DF4455EQ33769709-2BA447B0-A92F-49C9-B68A-F01385DF256EQ33771842-DBFFB7FA-DB93-4A80-8D94-1F2E694DBF4DQ34568353-446041D1-AEC5-42E0-875F-1E5342B38D7CQ34585615-9BAD0614-69A6-4DD2-8D4D-66BDADEFD3B6Q34910746-28BAB893-E545-4586-8AE8-827C5FB5F148Q34983483-79B1BA87-F9E7-4002-B652-6E4DD02DA2B7Q34983488-018990E1-DEC0-4884-8982-F4A2564B0470Q34996471-688A446F-3F0B-4766-AD08-493A6685CFCEQ35144333-1C35D2EE-A3B2-4CC5-83E2-45A31829E486Q35210204-F2D6817A-A7CD-427F-BC4D-F3CD49D4025BQ35575555-51DC1540-69D1-48AB-B2F5-4B1D0C87648FQ35645174-FE69955F-B726-4484-9823-C046F6E4CE07Q35842117-4D9601B9-FF9A-4D78-919C-DF444996EFD3Q35910779-8532FE4F-E4E0-467E-8AC0-84DD2EB82711Q35915201-609D0A7D-1634-4D11-B5DA-5FD39E1EF68AQ36084884-7164EFAC-4B21-4A32-A3AF-EC37A49CD022Q36246039-998CA9B0-EFAA-475A-8FEE-9612D5B2F5B6Q36507966-EBD48DE0-62A9-4E5C-BF40-83C81DFEE9CAQ36531030-93B1975F-97A6-402D-876B-DEC47604C978Q36633149-CEDA98B8-E03A-4066-AAFE-139CAF1470F8Q36753651-F1F4C0F1-5292-4DC8-9500-9E45D11EF6B7Q36753659-B0773E0E-D529-40C2-9333-459CA69F2ECAQ36753663-37F105B9-2259-4507-AE76-E4B10E5AB24FQ36753667-9E7DC45D-66B7-4E01-B1A3-FD19F5A8C707Q36758594-6321DFCC-353B-4700-AE76-CF2BCAC6BD6EQ36779635-9520806A-A1E1-4ACA-8B32-B49CE6C12AB2Q36820889-FCDA582D-88B6-433A-B22E-B961EC766D17Q36876679-2F34E66A-2A01-4FAB-B325-FAFFF50DAF53Q36951918-DA6067A5-FF1C-4B6C-A656-E139E751993AQ37121649-E348B3A2-3A4B-4703-A3AD-01AAF6BB016A
P50
name
Walter P Maksymowych
@en
type
label
Walter P Maksymowych
@en
prefLabel
Walter P Maksymowych
@en